Docetaxel significantly increases survival for incurable gastric cancers

January 23, 2013
Docetaxel significantly increases survival for incurable gastric cancers

Survival for advanced stomach and oesophagael cancer patients increases by 40 per cent when treated with the chemotherapy drug, Docetaxel – providing evidence to prescribe it as a second-line treatment, according to the results of a Cancer Research UK trial presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal cancers symposium today (Wednesday).

Patients with the advanced disease who do not respond to the initial standard treatment of platinum and fluoropyrimidine chemotherapy have very low survival – around four months. And in all patients with advanced disease and most of those with early disease (70 per cent) their cancer will eventually progress further after chemotherapy.

But these new results show that patients taking lived, on average, more than 40 per cent longer – 5.2 months compared with 3.6 months. The drug improved symptoms, without affecting quality of life.

Docetaxel is a chemotherapy drug usually given to treat breast, prostate and non-small cell lung cancer.

The trial, called COUGAR-02 was coordinated by the Cambridge Centre at Addenbrooke's hospital.

It recruited 168 patients from 31 UK hospitals with incurable oesophageal or stomach cancer after initial therapy.

They were then randomly assigned either chemotherapy for up to 18 weeks with Docetaxel, or symptom-control treatment with no chemotherapy.

Chief investigator Dr Hugo Ford, Cancer Research UK-funded clinician at Cambridge University Hospitals, said: "This is important progress for stomach and patients. At the moment there aren't any options for patients whose first round of treatments haven't worked and there's an urgent need for new drugs.

"But for the first time we've shown that giving further chemotherapy can not only improve survival but also maintain quality of life and reduce pain.

"It's incredibly hard as a clinician telling a patient with advanced disease that there are no treatments that will work for them. So it's fantastic that these results will provide new hope and valuable extra time for people and their families who otherwise would have no option other than pain management drugs."

Each year more than 12,000 people die from oesophagus or stomach cancer in the UK. Stomach cancer is one of the most common cancers worldwide.

Kate Law, Cancer Research UK's director of clinical research, said: "These exciting results from our trial provide the evidence that Docetaxel is effective when patient's initial treatment for advanced stomach cancer wasn't effective.  

"Our scientists were among the first to show that the major cause of stomach cancer is a common infection of the stomach lining by the bacterium Helicobacter pylori (H. pylori). This work has underpinned current research aimed at preventing . And we're delighted that this latest study will provide new, long overdue treatment options for these patients.

"We hope that Docetaxel can be made available on the NHS as soon as possible to treat the disease."

Explore further: Phase III trial shows crizotinib superior to single-agent chemotherapy for ALK-positive lung cancer

Related Stories

Phase III trial shows crizotinib superior to single-agent chemotherapy for ALK-positive lung cancer

September 30, 2012
The results of a new phase III trial show that crizotinib, a targeted therapy, is a more effective treatment than standard chemotherapy for patients with advanced, ALK-positive lung cancer, researchers said at the ESMO 2012 ...

Phase 3 trial confirms abiraterone acetate efficacy for patients with advanced prostate cancer

September 17, 2012
Results of a phase 3 trial published in The Lancet Oncology have confirmed that the drug abiraterone acetate (marketed as Zytiga) offers a significant survival benefit to patients with castration-resistant prostate cancer, ...

Phase 3 trial finds no benefit from atrasentan added to chemo for advanced prostate cancer

April 21, 2011
A Data and Safety Monitoring Committee (DSMC) has determined that patients in a phase III clinical trial given atrasentan in addition to a standard chemotherapy regimen for advanced prostate cancer did not have longer survival ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.